MindBio Therapeutics has announced positive topline results from its take-home phase 2a clinical trial of MB22001 in patients with depression, according to a company press release.
A proprietary self-titratable form of lysergic acid diethylamide (LSD) in microdoses for take-home use, the novel therapeutic allows patients to dose up or down depending on their tolerance.
“We are delighted to share that MB22001 showed rapid and statistically significant improvements with 60% reduction in depressive symptoms and 53% of patients experiencing complete remission from depression,” MindBio